BioPharm Asia, Inc. (OTC: BFAR)

BioPharm Asia, Inc. (OTC: BFAR)

COMPANY OVERVIEW

BioPharm Asia, Inc. (BioPharm Asia) is an U.S. listed company, primarily engaged in medicine chain business and complemented by a serial industry integrated business including cultivation of Chinese herbal medicine, pharmaceutical production and medicine wholesale.

In the wake of successful acquisitions of:

• Yunnan SiLin Pharmaceutical Commercial Co., Ltd. (Yunnan SiLin)
• Tonghua Huachen Pharmaceutical Co., Ltd. (Huachen Pharmaceutical)
• Tonghua Huachen Chinese Herbal Planting Co., Ltd. (Huachen Herbal)
• Beijing Zhihe Ruikang Hospital Management Ltd.

Through China North Pharmacy Company (CNPC), BioPharm Asia has preliminarily completed the integration of industry chain, extending the sole trading business (including terminal chain stores, distribution and wholesales business) to pharmaceutical manufacturing and cultivation of medicinal raw materials.

In 2008, the total revenue of BioPharm Asia’s China branches reached to $94 million USD, and $14 million USD generated in after-tax income approximately. Total 383 chain drug stores of Tonghua ShengAnTang were spread all over Jilin province of China, and Yunnan SiLin has established its mature distribution net of medicines covering northeast and southwest regions. The annual production capacity of Huachen Pharmaceutical includes tablets 120 million, capsule 150 million, 40 million packets of granule and 200 million bottles of oral solution. Furthermore, Huachen Herbal invested to build a GAP demonstration park where the total planting area covered 233 ha.

Starting from 2009, BioPharm Asia has been taking great effort to extend its industry scale in China. By 2011, BioPharm is estimated to complete its chain drugstores sales system establishment, accomplishing with various medicine production capacity, covering Chinese prepared medicines, western medicines, Tibetan medicines and Yi ethnic medicines, and become a large pharmaceutical industry investment group with international integrated marketing capability.

COMPANY STRUCTURE

PRODUCTS

Huachen Pharmaceutical’s major product portfolio in market has developed to more than 30 varieties, including the new created of “National Three Types of Chinese Medicines” which possessed the independent intellectual property right – “Qiweixiaoke Capsule“, and the National Protected Varieties of Chinese Medicines such as “Shengn Bujin Tablets“, “Tongqiaobiyan Tablets“, “Wujiarongxue Oral Solution” and Methocarbamol Capsule. Presently, these products are listed in drugstores around China and well accepted by consumers for outstanding effect of products.

Table 1. Major Varieties:

Qiweixiaoke Capsule is a new medicine of BioPharm Asia which classified in National Three Varieties of Chinese Medicine, and owns the national sole Independent Intellectual Property. This product is highly effective without any side effects, and BioPharm Asia is the only producer in the industry of Three Varieties of National Pure Traditional Chinese Medicine. 5 years left on the medicine intellectual property protection, and will be expired on 2013. Another is a Chinese Medicine variety under national protection – “Bujin Tablets“, and also the first protection variety in China.

LEADERSHIP

Xia Yang Hu, Chief Executive Officer
Mr. Hu, age 48, was Vice President of BioPharm Asia, Inc. from August 2009 to February 2011, was Bei Da Zong Heng Management Consulting Co., Ltd. from October 2008 to August 2009, Partner, Guang Dong Lipusheng Medical Apparatus and Instruments Biotechnology Co., Ltd. from May 2001 to October 2008, Chief Executive Officer, from May 1999 to May 2001, General Manager Assistant of Sirona Germany, from February 1992 to May 1999, Vice Manager of Guangzhou Eastern People Group Medicine & Health Products Co., Ltd. from July 1989 to February 1992, Industrial Engineer of Guangzhou Medicine Industrial Research Institution.

Chun Rong Xiong, Chief Financial Officer
Ms Xiong, age 42, was finance manager of Dong Guan Bencao Medicine Co., Ltd from February 2003 to January 2011; was a senior consultant with Dong Hai Accounting Firm from September 1998 to February 2003; from 1995 June to September 1998, she served as an accounting supervisor in Kangmei Pharmaceutical Co., Ltd; from July 1992 to June 1995, she was a cost accountant in Hua Zhong medicine Co. Ltd.

MAJOR CLIENTS

BioPharm Asia established a complete and efficient sales network, including 71 professional medical institutions dedicated in pulmonary and heart disease research, 121 Secondary and Integrated hospitals, a sales team consist by 271 full time employees, 19 provincial offices around China and lower divisions in most cities,
and consummated the sales network consisting 28 provinces and cities. Professional, standardized and systematic marketing team equipped with competence of depth distribution and academic promotion, ensures BiaPharma Asia’s product’s nationwide popularity and highly acceptance from patients. Furthermore, Huachen Pharmaceutical developed the solid co-operation in academic promotions with many hospitals. The company adheres to interactive relations between OTC depth distribution and RX academic promotions, successfully deepened the distribution channels and extended
to terminals.

For additional information on subsidiaries, strategic planning, R&D, and industry analysis visit http://www.biopharmasiainc.com/